The Quietmind Foundation (QMF) - Baylor Scott & White Research Institute (BSWRI),  published trial confirmed that self-administered, brief, 1070nm light stimulation improved both cognitive, motor and mood symptoms associated with early to mid-stage Alzheimer's and Parkinson's disease. QMF now is providing a 12-24 month. single-subject program combining 1070 transcranial and intranasal photobiomodulation with neurofeedback training.  

The program fee includes all equipment, quarterly qEEG and neuropsychological assessments, monthly photobiomodulation and neurofeedback training program monitoring and protocol revision.  All services are provided remotely at the subject's home excluding qEEG assessments. 

All inclusive participant fee: $10,000 (12 months) and $18,000 (24 months).
​Contact Dr. Berman for details at [email protected]

Click the link below to review the Baylor Scott & White Photobiomodulation clinical trial.  

1transcranial_near_infrared_light_stimulations_improve_cognition_in_patients_with_dementia.pdf
File Size:	470 kb
File Type:	pdf

Download File

---

Randomized Double-Blind Placebo-Controlled Clinical Trial
In cooperation with Texas A&M University's Dept. of Neurosurgery, Quietmind Foundation enrolled 100* subjects age 50-85 years experiencing memory problems and who had been independently diagnosed with early to mid-stage dementia to participate in this trial. The study used low-level infrared light stimulation directed to the head. The stimulation sessions were conducted at home, twice daily, for 6 minutes over 60 consecutive days. The trial was randomized, placebo controlled and double blinded.
Trial Procedure:
Individuals that matched the clinical trial eligibility criteria went through two unique assessments at the start, mid-point, and ending of the trial period. 

1. First, subjects completed a eyes open and closed 19-channel Quantitative EEG assessment. This assessment involved wearing a cap with sensors that records brain's electrical activity. This in person, non-invasive procedure is completed in less than 30-minutes
2. Subjects then completed a standardized memory assessment. This assessment takes an hour and was conducted by the study neuropsychologist. Some assessments are now completed remotely using teleconference connections, e.g., Zoom or Google Meet.

Following these first two assessments, participants received a Cognitolite transcranial photobiomodulation device and wore it for 6-minutes, twice daily for 2 months. This device used 1070nm LED lights that were intended to stimulate cortical blood flow and reduce inflammation.

Participants repeated the EEG and cognitive assessments twice more during the two month trial. Results  for the reported sample (N=69) were significantly positive. (Download publication above for details.)​

* Note: Results reported in the published paper are limited to the Texas cohort (N=69) and include only pre and post treatment neuropsychological testing results. Preparation of additional results including QEEG and additional subjects in the Philadelphia cohort are being developed. 

Marvin Berman, PhD CBT is Quietmind Foundation's founder and President and study co-investigator